Vertex stock jumps as rival cystic fibrosis drug fails trial

2 sources ·2 articles ·Aug 10, 16:22 UTC Vertex

2 outlets - including Biopharmadive and Investing - are covering this story. Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

Covered by 2 outlets

Biopharmadive 1 Investing 1

All coverage · 2 articles

BioPharma Dive ·Aug 10, 16:22 UTC

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

Investing.com Stock Market ·Aug 10, 14:02 UTC

Vertex stock jumps as rival cystic fibrosis drug fails trial

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex →

Vertex stock jumps as rival cystic fibrosis drug fails trial →

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Vertex stock jumps as rival cystic fibrosis drug fails trial